Zeo ScientifiX (Zeo ScientifiX) Change In Receivables : $-16 Mil (TTM As of Jan. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Change In Receivables?

Zeo ScientifiX's change in receivables for the quarter that ended in Jan. 2024 was $-59 Mil. It means Zeo ScientifiX's Accounts Receivable increased by $59 Mil from Oct. 2023 to Jan. 2024 .

Zeo ScientifiX's change in receivables for the fiscal year that ended in Oct. 2023 was $0 Mil. It means Zeo ScientifiX's Accounts Receivable declined by $0 Mil from Oct. 2022 to Oct. 2023 .

Zeo ScientifiX's Accounts Receivable for the quarter that ended in Jan. 2024 was $77 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zeo ScientifiX's Days Sales Outstanding for the three months ended in Jan. 2024 was 6.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zeo ScientifiX's liquidation value for the three months ended in Jan. 2024 was $-2,552 Mil.

Zeo ScientifiX Change In Receivables Historical Data

The historical data trend for Zeo ScientifiX's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Change In Receivables Chart

Zeo ScientifiX Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Change In Receivables

Get a 7-Day Free Trial

0.01

-0.08

-0.12

0.02

Zeo ScientifiX Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Receivables	Get a 7-Day Free Trial															-43.00	42.96	0.06	-	-59.00

Zeo ScientifiX Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16 Mil.

Zeo ScientifiX (OTCPK:ZEOX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zeo ScientifiX's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	77	/	1154	*	91
=	6.09

2. In Ben Graham's calculation of liquidation value, Zeo ScientifiX's accounts receivable are only considered to be worth 75% of book value:

Zeo ScientifiX's liquidation value for the quarter that ended in Jan. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1172	-	3940	+	0.75 * 77	+	0.5 * 316
=	-2,552

Zeo ScientifiX Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zeo ScientifiX (Zeo ScientifiX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

3321 College Avenue, Suite 246, Davie, FL, USA, 33314

Website

https://www.organicell.com

Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.

Executives

Skycrest Holdings, Llc	10 percent owner	1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider	director, officer: CEO and Director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub	officer: Executive Vice President & CSO	23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich	officer: COO and Acting CEO	4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser	director	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn	director	2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz	director	58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi	director	6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh	director	E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste	director
Ryan C Likes	officer: Chief Operating Officer	1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey	10 percent owner	GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell	10 percent owner, officer: Chief Financial Officer	77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani	director, officer: Chief Executive Officer	4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140